Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8<sup>+</sup> T-cell activation.

BMC medicine·2026
Same author

Kyphoscoliotic Ehlers-Danlos syndrome due to a novel homozygous PLOD1 variant: severe vascular involvement and molecular diagnosis.

BMC medical genomics·2026
Same author

Callicarpa nudiflora-derived extracellular vesicle-like particles loaded with budesonide enhance the treatment of ulcerative colitis by regulating M1/M2 macrophage polarization.

Biomaterials advances·2026
Same author

Low-Pass Genome Sequencing Reveals Associations Between Chromosomal Aberrations and Ultrasonographic Anomalies in a Cohort of 19,452 Fetuses.

Prenatal diagnosis·2026
Same author

Precise excision of expanded GGC repeats in NOTCH2NLC via CRISPR/Cas9 for treating neuronal intranuclear inclusion disease.

Nature communications·2026
Same author

Genetic characterization and screening of congenital adrenal hyperplasia by long-read sequencing in a cohort of 21,239 newborns.

Genome medicine·2025

相关实验视频

Updated: Jul 11, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K

准NKG2D-CAR的iPSC衍生MSC有效准表达NKG2D带的固体瘤.

Shuqing Tang1, Yusang Zhang1, Peiyun Wang1

  • 1Center for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences, Central South University, Changsha 410078, China.

iScience
|April 25, 2025
PubMed
概括

工程化介质干细胞 (iMSCs) 显示了瘤向的改进. 这些来自诱导多能干细胞 (iPSCs) 的iMSCs通过更好地定位到瘤来增强癌症治疗的交付.

关键词:
生物科学 生物科学癌症 癌症 癌症 癌症癌症系统生物学癌症系统生物学细胞生物学 细胞生物学分子生物学分子生物学自然科学 自然科学系统生物学 系统生物学

更多相关视频

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

2.8K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

590

相关实验视频

Last Updated: Jul 11, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.3K
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

2.8K
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

590

科学领域:

  • 生物技术是生物技术.
  • 癌症研究 癌症研究
  • 干细胞疗法 干细胞疗法

背景情况:

  • 介质细胞干细胞 (MSC) 在癌症治疗中表现有前途,但患有瘤定位和异质性差.
  • 诱导多能干细胞 (iPSC) 衍生的MSCs (iMSCs) 提供了一个更加均的替代品.
  • 加强iMSC瘤向对于有效的癌症治疗至关重要.

研究的目的:

  • 开发具有增强瘤向能力的iMSC.
  • 调查NKG2D - 化学原体受体 (CAR) 工程在iMSC中的疗效.
  • 评估工程iMSCs对瘤细胞的体外和体内定位和结合.

主要方法:

  • 通过准iPSC中的B2M位点来生成NKG2D-CAR-iPSC.
  • 将 NKG2D-CAR-iPSC 分化为 NKG2D-CAR-iMSC.
  • 在实验室中评估了瘤细胞的迁移和粘附.
  • 进行RNA测序以分析基因表达变化.
  • 在A549异种移植小鼠模型中评估瘤定位.

主要成果:

  • NKG2D-CAR工程显著增强了iMSC迁移和对表达NKG2D配体的瘤细胞的粘附.
  • RNA-seq揭示了NKG2D-CAR-iMSCs中与细胞粘附和迁移相关的基因的上调.
  • 在异种移植模型中,NKG2D-CAR-iMSCs与未经修改的iMSC相比,在瘤定位方面表现出57%的改善.

结论:

  • NKG2D-CAR-iMSCs对表达NKG2D配体的瘤细胞表现出卓越的向特异性.
  • 这种工程细胞疗法显示出作为一种现成的活体载体的潜力,用于向的抗癌药物输送.
  • 对NKG2D-CAR-iMSCs进行进一步的研究是有必要的,以便推进癌症治疗.